IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Hitoshi BAN et al.	
Application No. 10/576,581	Confirmation No. 2390
Filed: April 20, 2006	Art Unit: 1625
For: NOVEL PIPERIDINE DERIVATIVE	Examiner: D. K. O'Dell

INFORMATION DISCLOSURE STATEMENT (SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE OR CONCURRENTLY WITH A RULE 1.114 RCE APPLICATION)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Madam:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-SB08(s), attached hereto.

II. COPIES

\boxtimes	a.	Copies of	f cited I	J.S.	patents	and	patent	application	publications	are not	included.
Copies	of forei	gn patent	docum	ents	and nor	ı-pat	ent lite	rature are in	cluded.		

	b.	Some or all of the documents listed on the PTO-SB08 are not enclosed because
they	were o	cited in the International Search Report and copies should already be in the PTO file
If co	pies ar	re needed, please contact the undersigned.

Application No.: 10/576,581

2 DRN/II

Docket No.: 0020-5482PUS1

b. a continuat	This Information Disclosure Statement is being filed concurrent with the filing or ion-in-part, continuation, or divisional patent application; therefore, no fee is required
	This Information Disclosure Statement is being filed within three months of the of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required in is not to be used with RCE's.)
	This Information Disclosure Statement is being filed within three months of the y of the national stage as set forth in § 1.491 in an international application (37 C.F.R.)). No fee or statement is required.
☐ e. of a Reque statement is	This Information Disclosure Statement is being filed concurrently with the filing est for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or s required.
that a first (§ 1.97(c) a	This Information Disclosure Statement is being filed before the mailing date of a on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required. In the event Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been see our deposit account for the fee as required by 37 C.F.R. § 1.17(p).
	This Information Disclosure Statement is being filed before the mailing date of a exaction under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing otice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)). No statement; therefore, a fee as required by 37 C.F.R. § 1.17(p) is attached. or
(che	See the statement below. No fee is required. TEMENT UNDER 37 C.F.R. § 1.97(e) ck only one box) undersigned hereby states that:

Application No.: 10/576,581

3 DRN/II

Docket No.: 0020-5482PUS1

a. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this IDS; or b. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or No item of information contained in the IDS was cited in a communication from a c. foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS. d. Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement. VI. PAYMENT OF FEES (check one box) The required fee is listed on the attached Fee Transmittal. X No fee is required. If the Examiner has any questions concerning this IDS, he/she is requested to contact the

undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is

Application No.: 10/576,581

4 DRN/II

Docket No.: 0020-5482PUS1

Application No.: 10/576,581 Docket No.: 0020-5482PUS1

requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: May 15, 2009

Respectfully submitted,

By my	20
Mark J Nuell	

Registration No.: 36,623

BIRCH, STEWART, KOLASCH & BIRCH, LLP

12770 High Bluff Drive, Suite 260 San Diego, California 92130

(703) 205-8000

Attorney for Applicant

Attac	chments:
\boxtimes	PTO/SB/08
\boxtimes	Documents
\boxtimes	Foreign Search Report
	Fee
	Other